Spore-Based Probiotics
Bacillus Endospore-Forming Bacteria
Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.
8 human trials, about 120 studies, ~3,000 participants across strains. The written rationale for this grade is still being prepared.
- FDA
- Varies by product
- WADA
- Not prohibited
Reference only. Not medical advice.
What can go wrong
For most healthy adults, Bacillus spore probiotics have been well tolerated in trials with few reported adverse events. However, published case reports document Bacillus clausii bacteremia and sepsis following probiotic use, including in critically ill ICU patients (one case fatal) and even in immunocompetent hosts, including a young child with prolonged bacteremia. The safety of spore-based and other probiotics in immunocompromised, critically ill, or central-line patients is genuinely uncertain, and infection with the supplemented organism has been documented. Long-term human safety and microbiome data remain limited. Anyone who is immunocompromised, seriously ill, pregnant, or considering these products for a child should consult a qualified healthcare provider before use rather than self-treating.
Spore-based probiotics are formulations of Bacillus species, most often B. coagulans, subtilis, clausii, and indicus, delivered as dormant endospores whose multilayered coat lets them survive stomach acid, heat, and shelf storage where most Lactobacillus organisms die. In a human ileostomy study, ingested B. subtilis DE111 spores reached the small intestine and germinated into active cells within about three hours, and animal work shows germination concentrated in the jejunum and ileum. Survival, however, is not the same as clinical benefit: the germinated cells are transient and do not permanently colonize, and outcome evidence is uneven. It is genuinely moderate for Bacillus coagulans in IBS, and thinner and often industry-linked for the endotoxemia and immune claims marketed across the category. Makers position survivability as the category's core advantage; the open question is what that delivery reliably changes.
Heat- and acid-proof bacteria that survive where Lactobacillus dies. The survivability category.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
What people get wrong
Often saidSurviving stomach acid means the probiotic works
ActuallySurvival is a delivery property, not a clinical outcome. The human ileostomy RCT of DE111 (Colom et al., 2021) confirms spores reach and germinate in the small intestine, but demonstrated benefit is species- and indication-specific: moderate for Bacillus coagulans in IBS (7-RCT meta-analysis, 2023), and thinner and often industry-funded for the endotoxemia and immune claims (McFarlin et al., 2017, n=26, part-funded by Microbiome Labs).
Often saidSpores will overgrow and take over your gut
ActuallyGerminated Bacillus cells are transient. Casula and Cutting (2002) recovered only about 1 to 12 percent of the inoculum and found brief germination in the jejunum and ileum followed by clearance, with no permanent colonization; sustained dominance in a healthy gut has not been demonstrated.
Often saidSpore probiotics are risk-free because they are natural and shelf-stable
ActuallyFor most healthy users adverse events in trials are rare, but published case reports document Bacillus clausii bacteremia and sepsis after probiotic use, including in critically ill ICU patients (one fatal) and even in immunocompetent hosts such as a 17-month-old with 111 days of bacteremia. Regulatory bodies and clinicians advise caution in immunocompromised and critically ill patients.
Often saidSpore probiotics reliably harm microbiome diversity
ActuallyHuman and model data actually run the other way in the studies available: B. subtilis DE111 increased alpha-diversity indices in RCTs, and a SHIME model of a five-strain spore blend raised diversity and short-chain fatty acid output. Whether bacteriocin-producing strains reduce diversity in some individuals over the long term is genuinely unresolved, not established.
Who profits, and who pushes back
Simon M. Cutting
In the Casula and Cutting germination work, Bacillus spores germinate in the jejunum and ileum but are recovered at only about 1 to 12 percent of the inoculum and are largely cleared within a day, indicating the bacteria transit and do not permanently colonize the gastrointestinal tract.
Authors, Bacillus clausii Bacteremia: A Report of Two Cases
In two critically ill ICU patients, Bacillus clausii bacteremia developed within 48 hours of probiotic administration and one patient died; the authors conclude the efficacy and safety of probiotics for diarrhea in critically ill patients is unclear and urge caution.
Authors, prolonged B. clausii bacteraemia in an immunocompetent child
A 17-month-old immunocompetent girl developed 111 days of Bacillus clausii bacteremia after Enterogermina use, showing that spore probiotics can cause prolonged bacteremia even in immunocompetent hosts and warranting clinician vigilance.
Dr. Tina Anderson
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Leading commercial advocate for the category; sells spore products.
Functional-medicine practitioners
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Increasingly favor spore-based for survivability; many resell them.
Where the research comes from
| Place | Share of published research |
|---|---|
| USA | 40% |
| Europe | 30% |
| Asia | 18% |
| Other | 12% |
Research published from: Global.
How we got here
Bacillus probiotics were used clinically in Europe and Asia long before the modern survivability pitch. Enterogermina, a Bacillus clausii formulation, was registered as a pharmaceutical in Italy in 1958 and later sold over the counter, and B. clausii and B. coagulans preparations have been used across India and other parts of Asia for diarrheal illness for decades. Soil-derived Bacillus organisms sit within older traditions in many regions of eating fermented and soil-associated foods. The modern narrative crystallized in the 2000s, when laboratories including Simon Cutting's characterized how endospores survive gastric transit and germinate in the small intestine. As practitioners grew frustrated with the gap between labeled CFU counts and what actually reached the gut in conventional products, direct-to-consumer brands built a category around the structural survivability advantage during the 2010s.
- 1958Bacillus clausii formulation (Enterogermina) registered as a pharmaceutical in Italy
- 1980s-1990sBacillus clausii and coagulans preparations used for diarrhea across Europe and Asia; Enterogermina moves over the counter by 1999
- 2002Casula and Cutting show Bacillus spores germinate in the jejunum and ileum and transit rather than permanently colonize (animal model)
- 2010sDirect-to-consumer spore brands build the survivability category
- 2017McFarlin et al. report a spore-blend endotoxemia pilot, part-funded by Microbiome Labs
- 2021Human ileostomy RCT confirms B. subtilis DE111 spores survive gastric transit and germinate in the small intestine within 3 hours
- 2023Systematic review and meta-analysis of 7 RCTs reports B. coagulans improves IBS symptom severity and abdominal pain
At a glance
- Form
- Endospore (dormant)
- Survives
- Stomach acid, heat, shelf
- Germinates
- In small intestine pH
- Key species
- coagulans, subtilis, clausii
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Spore-Based Probiotics. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
B. subtilis DE111 spores survive gastric transit and germinate in the human small intestine within 3 hours; RCT part-funded by Deerland (manufacturer)
Bacillus spores germinate in the jejunum and ileum, only ~1-12% of inoculum recovered, transit rather than permanently colonize (animal model)
Casula and Cutting, Applied and Environmental Microbiology (via PMC)
Spore-based blend associated with 42% endotoxin and 24% triglyceride reduction; small pilot (26 randomized responders), part-funded by Microbiome Labs
McFarlin et al., World Journal of Gastrointestinal Pathophysiology (PubMed)
Meta-analysis of 7 RCTs finds Bacillus coagulans improves IBS symptom severity and abdominal pain with no serious adverse events
Systematic review and meta-analysis, Clinical Nutrition ESPEN / ScienceDirect (2023)
Synbiotic containing B. coagulans significantly reduced IBS abdominal pain vs placebo in an RCT (n=85 enrolled)
Network meta-analysis ranks B. coagulans strains highly for abdominal pain in IBS
Outcome-Specific Efficacy of Probiotics in IBS, Nutrients (via PMC)
Two ICU patients developed B. clausii bacteremia within 48 hours of probiotic use; one died; authors urge caution in critically ill patients
Bacillus clausii Bacteremia: A Report of Two Cases (via PMC)
Immunocompetent 17-month-old developed 111 days of B. clausii bacteremia after Enterogermina; spore probiotics can cause prolonged bacteremia even in immunocompetent hosts
Prolonged B. clausii bacteraemia in an immunocompetent child, Access Microbiology (via PMC)
Bacillus clausii (Enterogermina) registered as a pharmaceutical in Italy in 1958 and later available over the counter; long real-world use
PEGASO real-world study, Drugs Real World Outcomes (via Springer)